Cell line · CVCL_1561
NCI-H441
Cancer cell line, Homo sapiens. Lung papillary adenocarcinoma. 67 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. NCI-H441. Cell lines, record CVCL_1561. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1561
On this page
Cell line
As Cellosaurus gives it.
- Name
- NCI-H441
- Accession
- CVCL_1561
- RRID
- RRID:CVCL_1561
- Synonyms
- H441, H-441, NCI-H441-4, NCI-441, NCIH441
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 33Y
- Category
- Cancer cell line
- Diseases
- Lung papillary adenocarcinoma (NCIt C5650)
- Derived from
- Pericardial effusion (metastatic)
- Cell type
- Club cell
- Entry created
- 2012-04-04
- Entry updated
- 2025-08-14
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers67
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Ionomycin suppresses cancer cell growth by disrupting mitochondrial transcription. | FEBS Open Bio | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Biomolecular Condensates as Protein Degradation Tools for Intracellular Targets. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of LIMK by Cofilin-1 peptidomimetics enhances actin depolymerization and reduces metastasis of non-small cell lung cancer. | Oncogenesis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancer. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Antibodies blocking PlGF or VEGF interactions with the NRP1 receptor mediate antiproliferative effects. | J Biol Chem | 2026 | Its Methods give the RRID and name the line | PubMed | |
| KRASG12V/HLA-A*02:01-targeted chimeric antigen receptor T cells exhibit potent preclinical activity against solid tumors. | Sci Adv | 2026 | Its Methods give the RRID and name the line | Retracted | PubMed |
| Expanding the payload scope in antibody-drug conjugates by delivery of hydroxy-containing drugs through self-immolative phosphoramidates. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti-PD-1 Therapy. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting a Glutamic Acid in PDEδ with Fluoromethyl-Aryl Electrophiles Impairs K-Ras Signaling. | J Med Chem | 2026 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 67
See all 67 papersRelatives1
| Relation | Cell line | Accession | Problem |
|---|---|---|---|
| Derived from it | NCI-H441/CMV-Luc | CVCL_M254 |
Source Cell lines
Cell banks8
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | CRM-HTB-174 | ATCC | |
| ATCC | HTB-174 | ATCC | |
| AddexBio | C0016019/4975 | Cellosaurus | |
| BCRC | 60455 | BCRC | |
| BCRJ | 0359 | BCRJ | |
| CCTCC | GDC0308 | Cellosaurus | |
| CLS | 305219 | CLS | |
| IZSLER | BS TCL 215 | Cellosaurus |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1561
GET https://conductscience.org/api/cell-lines/v1/CVCL_1561/papers?page=2